

## Melanoma Research and Therapy Special Interest Group Meeting

Friday 26 June 2020

<b>Time and date:</b>	10.00 am – 1.00 pm Friday 26 June 2020													
<b>Venue:</b>	To be held online via Zoom													
<b>Chairs:</b>	Dr Jody Jordan													
<b>Agenda:</b>	<table border="1"> <tr> <td>10.00 am</td> <td>Welcome and introductions</td> </tr> <tr> <td>10.15 am</td> <td>National melanoma immunotherapy database <i>Presentations from Associate Professor Peter Gibbs (Royal Melbourne Hospital) and Alexander Dunn (Cancer Control Agency) followed by discussion.</i></td> </tr> <tr> <td>11.45 am</td> <td>PHARMAC Special Authority criteria: Temporary removal of specified dose regimen for nivolumab and pembrolizumab during COVID crisis <i>Feedback on changes to Special Authority criteria and discussion on appetite for continuing extended dosing regimens after COVID crisis stabilizes.</i></td> </tr> <tr> <td>12.00 noon</td> <td>Collaborative use of new genomic technologies to monitor melanoma <i>Presentation from Professor Cristin Print (University of Auckland) followed by discussion.</i></td> </tr> <tr> <td>12.45 pm</td> <td>Wrap up</td> </tr> <tr> <td>1.00 pm</td> <td>Close</td> </tr> </table>		10.00 am	Welcome and introductions	10.15 am	National melanoma immunotherapy database <i>Presentations from Associate Professor Peter Gibbs (Royal Melbourne Hospital) and Alexander Dunn (Cancer Control Agency) followed by discussion.</i>	11.45 am	PHARMAC Special Authority criteria: Temporary removal of specified dose regimen for nivolumab and pembrolizumab during COVID crisis <i>Feedback on changes to Special Authority criteria and discussion on appetite for continuing extended dosing regimens after COVID crisis stabilizes.</i>	12.00 noon	Collaborative use of new genomic technologies to monitor melanoma <i>Presentation from Professor Cristin Print (University of Auckland) followed by discussion.</i>	12.45 pm	Wrap up	1.00 pm	Close
10.00 am	Welcome and introductions													
10.15 am	National melanoma immunotherapy database <i>Presentations from Associate Professor Peter Gibbs (Royal Melbourne Hospital) and Alexander Dunn (Cancer Control Agency) followed by discussion.</i>													
11.45 am	PHARMAC Special Authority criteria: Temporary removal of specified dose regimen for nivolumab and pembrolizumab during COVID crisis <i>Feedback on changes to Special Authority criteria and discussion on appetite for continuing extended dosing regimens after COVID crisis stabilizes.</i>													
12.00 noon	Collaborative use of new genomic technologies to monitor melanoma <i>Presentation from Professor Cristin Print (University of Auckland) followed by discussion.</i>													
12.45 pm	Wrap up													
1.00 pm	Close													